Ironwood Pharmaceuticals Inc. (IRWD) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
100 SUMMER STREET, SUITE 2300 BOSTON, MA 02110 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 88,559 | 92,154 | 656,203 | 620,129 | 362,564 | 177,023 | |||
| Cash and cash equivalent | 88,559 | 92,154 | 656,203 | 620,129 | 362,564 | 177,023 | |||
| Restricted cash and investments | 1,250 | 1,250 | 1,735 | 1,250 | |||||
| Receivables | 81,886 | 129,122 | 115,458 | 114,042 | 122,351 | 117,246 | |||
| Inventory, net of allowances, customer advances and progress billings | 648 | ||||||||
| Inventory | 648 | ||||||||
| Derivative instruments and hedges, assets | 1,115 | ||||||||
| Other undisclosed current assets | 11,923 | 12,012 | 7,715 | 8,689 | 9,189 | 10,685 | |||
| Total current assets: | 182,368 | 233,288 | 780,626 | 745,225 | 495,839 | 306,852 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 11,028 | 12,586 | 14,023 | 15,350 | 16,576 | 17,743 | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 4,495 | 5,585 | 6,288 | 7,575 | 8,929 | 12,429 | |||
| Long-term investments and receivables | 14,589 | 23,998 | 23,401 | 32,597 | |||||
| Accounts and financing receivable, after allowance for credit loss | 14,589 | 23,998 | 23,401 | 32,597 | |||||
| Intangible asset, including goodwill, after accumulated amortization | 2,860 | 3,682 | 785 | ||||||
| Goodwill | 785 | ||||||||
| Intangible asset, excluding goodwill, after accumulated amortization | 2,860 | 3,682 | |||||||
| Derivative instruments and hedges | 13,065 | 31,366 | |||||||
| Restricted cash and investments | 485 | 485 | 485 | 971 | |||||
| Deferred income tax assets | 144,234 | 212,324 | 283,661 | 333,294 | |||||
| Other noncurrent assets | 5,923 | 3,608 | 847 | 1,000 | 943 | 5 | |||
| Total noncurrent assets: | 168,540 | 237,785 | 319,893 | 381,702 | 63,399 | 95,896 | |||
| TOTAL ASSETS: | 350,908 | 471,073 | 1,100,519 | 1,126,927 | 559,238 | 402,748 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 26,384 | 43,781 | 17,183 | 21,530 | 18,237 | 34,264 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 300 | 1,600 | 301 | ||
| Taxes payable | ✕ | ✕ | ✕ | ✕ | 200 | ||||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 16,653 | 13,413 | 18,533 | ||
| Accounts payable | 2,127 | 7,830 | 483 | 935 | 661 | 3,978 | |||
| Accrued liabilities | 24,257 | 35,951 | 16,700 | 3,442 | 2,563 | 11,452 | |||
| Deferred revenue | 2,032 | 2,600 | 875 | ||||||
| Debt | 199,560 | 116,858 | 1,146 | ||||||
| Derivative instruments and hedges, liabilities | 19 | 1,316 | |||||||
| Restructuring reserve | 560 | 8,303 | 462 | 10,510 | 179 | ||||
| Estimated litigation liability | |||||||||
| Due to related parties | ✕ | ✕ | ✕ | 1,509 | |||||
| Other undisclosed current liabilities | 9,870 | 21,857 | 8,323 | 21,532 | 3,426 | 2,956 | |||
| Total current liabilities: | 38,846 | 276,101 | 25,525 | 161,698 | 32,173 | 40,929 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 583,988 | 498,309 | 396,251 | 355,817 | 450,574 | 430,076 | |||
| Long-term debt, excluding current maturities | 583,988 | 498,309 | 396,251 | 337,333 | 430,256 | 407,994 | |||
| Liabilities, other than long-term debt | 29,409 | 42,958 | 26,365 | 3,501 | 13,851 | 24,994 | |||
| Other liabilities | 17,105 | 28,415 | 9,766 | 3,501 | 1,763 | 734 | |||
| Operating lease, liability | 12,304 | 14,543 | 16,599 | 18,484 | 20,318 | 22,082 | |||
| Derivative instruments and hedges, liabilities | 12,088 | 24,260 | |||||||
| Total noncurrent liabilities: | 613,397 | 541,267 | 422,616 | 359,318 | 464,425 | 455,070 | |||
| Total liabilities: | 652,243 | 817,368 | 448,141 | 521,016 | 496,598 | 495,999 | |||
| Equity | |||||||||
| Equity, attributable to parent | (301,335) | (346,295) | 652,378 | 605,911 | 62,640 | (93,251) | |||
| Common stock | 160 | 156 | 154 | 162 | 161 | 158 | |||
| Additional paid in capital | 1,395,317 | 1,355,195 | 1,348,600 | 1,543,357 | 1,528,535 | 1,478,823 | |||
| Accumulated other comprehensive income (loss) | 923 | (3,031) | |||||||
| Accumulated deficit | (1,697,735) | (1,698,615) | (696,376) | (937,608) | (1,466,056) | (1,572,232) | |||
| Total equity: | (301,335) | (346,295) | 652,378 | 605,911 | 62,640 | (93,251) | |||
| TOTAL LIABILITIES AND EQUITY: | 350,908 | 471,073 | 1,100,519 | 1,126,927 | 559,238 | 402,748 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 351,410 | 442,735 | 410,596 | 413,753 | 389,523 | 428,413 | ||
| Cost of revenue | (2,593) | (1,096,323) | (3,136) | (23,875) | ||||
| Cost of product and service sold | (3,136) | (23,875) | ||||||
| Gross profit: | 348,817 | (653,588) | 410,596 | 413,753 | 386,387 | 404,538 | ||
| Operating expenses | (255,693) | (291,842) | (160,259) | (181,538) | (243,447) | (291,114) | ||
| Other undisclosed operating income | 44 | 6,699 | ||||||
| Operating income (loss): | 93,124 | (945,430) | 250,337 | 232,259 | 142,940 | 120,123 | ||
| Nonoperating income (expense) | (27,926) | (2,639) | 2,085 | (31,602) | (34,079) | (61,180) | ||
| Investment income, nonoperating | 4,468 | 18,990 | 9,683 | (452) | (4,625) | 5,885 | ||
| Interest and debt expense | (33,034) | (21,629) | (7,598) | (31,150) | (29,478) | (30,977) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | 32,164 | (969,698) | 244,824 | 169,507 | 79,383 | 27,966 | ||
| Other undisclosed income from continuing operations before income taxes | 33,034 | 21,629 | 7,598 | 31,150 | 29,478 | |||
| Income (loss) from continuing operations before income taxes: | 65,198 | (948,069) | 252,422 | 200,657 | 108,861 | 27,966 | ||
| Income tax expense (benefit) | (64,318) | (83,490) | (77,357) | 327,791 | (2,685) | |||
| Other undisclosed income from continuing operations | 30,977 | |||||||
| Income (loss) from continuing operations: | 880 | (1,031,559) | 175,065 | 528,448 | 106,176 | 58,943 | ||
| Income before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | 528,448 | 106,176 | 21,505 | |
| Loss from discontinued operations | (37,438) | |||||||
| Net income (loss): | 880 | (1,031,559) | 175,065 | 528,448 | 106,176 | 21,505 | ||
| Net income attributable to noncontrolling interest | 29,320 | |||||||
| Net income (loss) available to common stockholders, basic: | 880 | (1,002,239) | 175,065 | 528,448 | 106,176 | 21,505 | ||
| Other undisclosed net income available to common stockholders, diluted | 1,157,674 | 4,449 | ||||||
| Net income available to common stockholders, diluted: | 880 | 155,435 | 179,514 | 528,448 | 106,176 | 21,505 | ||
Comprehensive Income ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 880 | (1,031,559) | 175,065 | 528,448 | 106,176 | 21,505 | ||
| Other comprehensive income (loss) | 3,954 | (3,031) | ||||||
| Comprehensive income (loss): | 4,834 | (1,034,590) | 175,065 | 528,448 | 106,176 | 21,505 | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 63 | |||||||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 29,320 | |||||||
| Comprehensive income (loss), net of tax, attributable to parent: | 4,834 | (1,005,207) | 175,065 | 528,448 | 106,176 | 21,505 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.